Table 1 Baseline Characteristics
Parameters | Low PLR (n = 36) | High PLR (n = 35) | P Value |
|---|---|---|---|
Age, years | 57.97 ± 10.51 | 59.77 ± 8.88 | 0.439 |
Male, n (%) | 28(77.8%) | 26(74.3%) | 0.73 |
Type of ACS, n (%) | |||
 UAP | 29(80.6%) | 27(77.1%) | 0.725 |
 Non-STEMI | 4(11.1%) | 4(11.4%) | 0.966 |
 STEMI | 3(8.3%) | 4(11.4%) | 0.662 |
Hypertension, n (%) | 23(63.9%) | 17(48.6%) | 0.193 |
Diabetes mellitus, n (%) | 13(36.1%) | 13(37.1%) | 0.928 |
Dyslipidemia, n (%) | 15(41.7%) | 7(20.0%) | 0.048 |
Current smoker, n (%) | 15(41.7%) | 8(22.9%) | 0.09 |
Previous MI, n (%) | 12(33.3%) | 11(31.4%) | 0.864 |
LVEF, % | 0.65 ± 0.08 | 0.62 ± 0.08 | 0.262 |
Medical therapy | |||
 ASA, n (%) | 36(100.0%) | 35(100.0%) | 1.000 |
 P2Y12 receptor antagonist, n (%) | 34(94.4%) | 35(100.0%) | 0.493 |
 Statin, n (%) | 36(100.0%) | 35(100.0%) | 1.000 |
 RAS blocker, n (%) | 7(19.4%) | 16(45.7%) | 0.018 |
 β-blocker, n (%) | 15(45.7%) | 17(48.6%) | 0.559 |
 CCB, n (%) | 16(44.4%) | 11(31.4%) | 0.259 |